Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Society of Hematology | OTHER |
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
This is a two phase pilot study to develop and pilot the UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) program intervention that includes lymphoma survivorship information and acceptance and commitment therapy strategies to alleviate fear of cancer recurrence, reduce distress, and improve quality of life among lymphoma survivors.
Phase 1 will be a two-part development process of the UPLYFT program based on interview feedback from lymphoma and mental health clinicians and then feedback from a six-person group of lymphoma survivors after participation in an UPLYFT program field test. Phase 2 is a randomized pilot study using the UPLFYT program finalized in Phase 1.
Research procedures include:
In depth interview (lymphoma and mental health clinicians)
Screening for eligibility
6 weekly intervention sessions (lymphoma survivors)
Baseline Assessments and Questionnaires (lymphoma survivors)
74 people are expected to participate in this study with 14 in Phase 1 and 60 in Phase 2.
The American Society of Hematology is providing funding for the trial.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Clinicians Interviews | Experimental | Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program. |
|
| Lymphoma Survivors Field Test | Experimental | A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program. |
|
| UPLYFT Pilot | Experimental | Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program. Participants will be randomized 1:1 to either UPLYFT or usual care. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Interview with Clinicians | Other | One time, qualitative interview of clinicians for feedback on UPLYFT intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility: Enrollment Rate | Proportion of eligible patients approached that enroll in the study. | Up to 6 months |
| Feasibility: Program Session Completion Rate | Proportion of study participants randomized to the intervention arm (UPLYFT) who complete all intervention sessions. | Up to 6 months |
| Feasibility: Data Collection Completion Rate | Proportion of enrolled participants who complete assigned patient-reported questionnaires during the study. | Up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Acceptability: Satisfaction Rate | Satisfaction rate is defined as the proportion of study participants randomized to the intervention arm who are satisfied with the UPLYFT program and proportion who are likely to recommend the program. | Up to 6 months |
| Acceptability: Disenrollment Rate |
Not provided
Inclusion Criteria:
Lymphoma Survivors Phase 1 and 2:
Lymphoma clinicians and mental health clinicians Phase 1:
Exclusion Criteria:
Lymphoma Survivors Phase 1:
Lymphoma Survivors Phase 2:
Age < 18 years
Concurrent other malignancy
Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).
Our study will exclude members of the following special populations:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Oreofe O Odejide, MD, MPH | Contact | (617) 632-6864 | Oreofe_Odejide@dfci.harvard.edu |
| Name | Affiliation | Role |
|---|---|---|
| Oreofe O Odejide, MD, PhD | Oreofe_Odejide@dfci.harvard.edu | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dana-Farber Cancer Institute | Recruiting | Boston | Massachusetts | 02215 | United States |
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Data can be shared no earlier than 1 year following the date of publication
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
Not provided
Not provided
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D007407 | Interviews as Topic |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Field Test of UPLYFT with Lymphoma Survivors | Other | 6 session of UPLYFT intervention with Lymphoma Survivors for feedback |
|
| Pilot of UPLYFT with Lymphoma Survivors | Behavioral | 6 session of UPLYFT intervention with Lymphoma Survivors |
|
Disenrollment rate is defined as the proportion of eligible patients who enroll in the study who then choose to disenroll from the study. |
| Up to 6 months |
| Preliminary efficacy: Fear of Cancer Recurrence (FCR) Change | Pre-intervention to post-intervention changes in Fear of Cancer Recurrence (FCR) measured with the Fear of Cancer Recurrence Inventory (FCRI, 42-item questionnaire), with a focus on the FCRI severity subscale. | Up to 6 months |
| Preliminary efficacy: Quality of Life Change | Pre-intervention to post-intervention changes in quality of life measured with the Quality of Life- Cancer Survivor instrument (a 41-item questionnaire) | Up to 6 months |
| Preliminary efficacy: Anxiety Change | Pre-intervention to post-intervention changes in anxiety as measured by the Hospital and Anxiety Scale (Anxiety subscale) | Up to 6 months |
| Preliminary efficacy: Depression Change | Pre-intervention to post-intervention changes in depression as measured by the Hospital Anxiety and Depression Scale (Depression subscale) | Up to 6 months |
| Preliminary efficacy: Psychological inflexibility Change | Pre-intervention to post-intervention changes in psychological inflexibility as measured by the Acceptance and Action Questionnaire-II (a 7-item scale) | Up to 6 months |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |